These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Importance of oral glucose tolerance test in patient with schizophrenia. Margetić B; Aukst-Margetić B; Badanjak A Psychiatr Danub; 2005 Jun; 17(1-2):94-6. PubMed ID: 16395850 [TBL] [Abstract][Full Text] [Related]
46. RBC and plasma choline in neuroleptic-treated schizophrenic patients. Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429 [TBL] [Abstract][Full Text] [Related]
47. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670 [TBL] [Abstract][Full Text] [Related]
49. [Tardive dystonia--a case report on therapy and metaphylaxis]. Genz A Psychiatr Neurol Med Psychol (Leipz); 1988 May; 40(5):264-8. PubMed ID: 2905065 [TBL] [Abstract][Full Text] [Related]
50. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472 [TBL] [Abstract][Full Text] [Related]
52. Potential adverse effects of discontinuing psychotropic drugs. Part 3: Antipsychotic, dopaminergic, and mood-stabilizing drugs. Howland RH J Psychosoc Nurs Ment Health Serv; 2010 Aug; 48(8):11-4. PubMed ID: 20669865 [TBL] [Abstract][Full Text] [Related]
53. Treatment of clozapine-associated tardive dyskinesia. Lin CC; Bai YM; Chen JY; Wang YC; Liou YJ Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):599-600. PubMed ID: 17920744 [No Abstract] [Full Text] [Related]
54. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol]. Furukori H Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806 [TBL] [Abstract][Full Text] [Related]
55. Rational polypharmacy in the bipolar affective disorders. Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735 [TBL] [Abstract][Full Text] [Related]
56. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463 [TBL] [Abstract][Full Text] [Related]